CA2399421A1 - Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor - Google Patents
Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor Download PDFInfo
- Publication number
- CA2399421A1 CA2399421A1 CA002399421A CA2399421A CA2399421A1 CA 2399421 A1 CA2399421 A1 CA 2399421A1 CA 002399421 A CA002399421 A CA 002399421A CA 2399421 A CA2399421 A CA 2399421A CA 2399421 A1 CA2399421 A1 CA 2399421A1
- Authority
- CA
- Canada
- Prior art keywords
- alpha
- adrenoceptor
- disease
- antagonist
- selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18202100P | 2000-02-11 | 2000-02-11 | |
| US60/182,021 | 2000-02-11 | ||
| FI20000303A FI20000303A0 (fi) | 2000-02-14 | 2000-02-14 | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
| FI20000303 | 2000-02-14 | ||
| PCT/FI2001/000105 WO2001058454A1 (en) | 2000-02-11 | 2001-02-07 | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2399421A1 true CA2399421A1 (en) | 2001-08-16 |
Family
ID=26160944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002399421A Abandoned CA2399421A1 (en) | 2000-02-11 | 2001-02-07 | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1253926A1 (ru) |
| JP (1) | JP2003522148A (ru) |
| KR (1) | KR20020080413A (ru) |
| AU (1) | AU780802B2 (ru) |
| BR (1) | BR0108221A (ru) |
| CA (1) | CA2399421A1 (ru) |
| CZ (1) | CZ20022884A3 (ru) |
| EA (1) | EA200200846A1 (ru) |
| EE (1) | EE200200435A (ru) |
| GE (1) | GEP20043356B (ru) |
| HR (1) | HRP20020746A2 (ru) |
| HU (1) | HUP0300032A3 (ru) |
| IL (1) | IL151017A0 (ru) |
| IS (1) | IS6476A (ru) |
| MX (1) | MXPA02007454A (ru) |
| MY (1) | MY133957A (ru) |
| NO (1) | NO20023773D0 (ru) |
| NZ (1) | NZ520500A (ru) |
| PL (1) | PL357872A1 (ru) |
| SK (1) | SK11472002A3 (ru) |
| WO (1) | WO2001058454A1 (ru) |
| YU (1) | YU59102A (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000615A (es) * | 2001-07-20 | 2004-04-20 | Juvantia Pharma Ltd Oy | Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor. |
| FI116940B (fi) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416432D0 (en) * | 1984-06-28 | 1984-08-01 | Wyeth John & Brother Ltd | Benzoquinolizines |
| RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US6150389A (en) * | 1994-07-11 | 2000-11-21 | Allergan Sales, Inc. | Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents |
-
2001
- 2001-02-07 IL IL15101701A patent/IL151017A0/xx unknown
- 2001-02-07 CZ CZ20022884A patent/CZ20022884A3/cs unknown
- 2001-02-07 WO PCT/FI2001/000105 patent/WO2001058454A1/en not_active Application Discontinuation
- 2001-02-07 GE GE4893A patent/GEP20043356B/en unknown
- 2001-02-07 MX MXPA02007454A patent/MXPA02007454A/es unknown
- 2001-02-07 KR KR1020027010329A patent/KR20020080413A/ko not_active Application Discontinuation
- 2001-02-07 CA CA002399421A patent/CA2399421A1/en not_active Abandoned
- 2001-02-07 EP EP01907585A patent/EP1253926A1/en not_active Withdrawn
- 2001-02-07 AU AU35510/01A patent/AU780802B2/en not_active Ceased
- 2001-02-07 SK SK1147-2002A patent/SK11472002A3/sk unknown
- 2001-02-07 JP JP2001557564A patent/JP2003522148A/ja active Pending
- 2001-02-07 EA EA200200846A patent/EA200200846A1/ru unknown
- 2001-02-07 PL PL01357872A patent/PL357872A1/xx not_active Application Discontinuation
- 2001-02-07 YU YU59102A patent/YU59102A/sh unknown
- 2001-02-07 BR BR0108221-3A patent/BR0108221A/pt not_active IP Right Cessation
- 2001-02-07 EE EEP200200435A patent/EE200200435A/xx unknown
- 2001-02-07 HU HU0300032A patent/HUP0300032A3/hu unknown
- 2001-02-07 NZ NZ520500A patent/NZ520500A/en unknown
- 2001-02-09 MY MYPI20010579A patent/MY133957A/en unknown
-
2002
- 2002-07-19 IS IS6476A patent/IS6476A/is unknown
- 2002-08-09 NO NO20023773A patent/NO20023773D0/no not_active Application Discontinuation
- 2002-09-11 HR HRP20020746 patent/HRP20020746A2/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU780802B2 (en) | 2005-04-21 |
| EE200200435A (et) | 2003-12-15 |
| HUP0300032A2 (en) | 2003-05-28 |
| EA200200846A1 (ru) | 2002-12-26 |
| CZ20022884A3 (cs) | 2003-02-12 |
| WO2001058454A1 (en) | 2001-08-16 |
| GEP20043356B (en) | 2004-04-13 |
| EP1253926A1 (en) | 2002-11-06 |
| HRP20020746A2 (en) | 2004-12-31 |
| BR0108221A (pt) | 2003-03-05 |
| HUP0300032A3 (en) | 2006-01-30 |
| AU3551001A (en) | 2001-08-20 |
| KR20020080413A (ko) | 2002-10-23 |
| NZ520500A (en) | 2005-01-28 |
| MY133957A (en) | 2007-11-30 |
| JP2003522148A (ja) | 2003-07-22 |
| YU59102A (sh) | 2005-11-28 |
| SK11472002A3 (sk) | 2003-02-04 |
| NO20023773L (no) | 2002-08-09 |
| IL151017A0 (en) | 2003-02-12 |
| PL357872A1 (en) | 2004-07-26 |
| NO20023773D0 (no) | 2002-08-09 |
| MXPA02007454A (es) | 2004-08-23 |
| IS6476A (is) | 2002-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhuo et al. | Intracellular ANG II induces cytosolic Ca2+ mobilization by stimulating intracellular AT1 receptors in proximal tubule cells | |
| JP5925121B2 (ja) | 副腎皮質ステロイド合成を阻害しないエトミデート類似体 | |
| Mizobe et al. | α2-Adrenoceptor agonists and anesthesia | |
| JP2002526408A (ja) | 疼痛および不安の処置のためのｍｇｌｕｒ５アンタゴニスト | |
| Salomonsson et al. | α1-Adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies | |
| Molderings et al. | Imidazoline binding sites and receptors in cardiovascular tissue | |
| Gentili et al. | Agonists and antagonists targeting the different α2-adrenoceptor subtypes | |
| TW445147B (en) | Pharmaceutical composition for preventing and treating postischemic renal failure and for protecting the ischemic kidney, comprising an AT1-receptor antagonist | |
| JP4380800B2 (ja) | マラリアの処置のための（＋）メフロキンの使用 | |
| WO2022095461A1 (zh) | 一种特异性增强TRPV4-KCa2.3复合体的空间耦联度的化合物及其用途 | |
| US6521632B2 (en) | Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor | |
| Creagh et al. | Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate | |
| CA2399421A1 (en) | Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor | |
| FI116940B (fi) | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet | |
| AU715350B2 (en) | Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects | |
| Miyazawa et al. | Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function | |
| JPWO2010095462A1 (ja) | 新規な３−（５−アルコキシピリミジン−２−イル）ピリミジン−４（３ｈ）−オン構造を有する化合物及びこれを含有する医薬 | |
| JP2004535467A (ja) | α−２Ｂ−アドレナリン受容体が介在する疾患を治療又は予防するために有用な化合物 | |
| WO2015008138A1 (en) | Novel ureido derivatives of naphthalenesulfonic acids | |
| Goldman et al. | Recent inventions on receptor tyrosine kinase RET modulation | |
| NAGATOMO et al. | Effect of 3-[2-[4-(o-Methoxyphenyl)-1-piperazinyl] ethyl]-2, 4 (1H, 3H)-quinazolinedione Monohydrochloride (SGB-1534), an Anthihypertensive Agent, on 3H-Prazosin and 3H-p-Aminoclonidine Binding to α1-and α2-Adrenoceptors in Dog Brain and Arta | |
| US20060058355A1 (en) | Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker | |
| AU2002319331A1 (en) | Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor | |
| KR20020045552A (ko) | 만성 폐색성 폐질환의 치료 방법 | |
| AU1955000A (en) | Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |